Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.125 | -1.64907651715 | 7.58 | 7.95 | 6.266 | 610395 | 6.89964362 | CS |
4 | -0.675 | -8.30258302583 | 8.13 | 9.18 | 6.266 | 484475 | 7.58885976 | CS |
12 | 0.425 | 6.04551920341 | 7.03 | 11.2 | 6.266 | 447742 | 8.34996927 | CS |
26 | -0.955 | -11.355529132 | 8.41 | 11.2 | 5.91 | 464599 | 8.06980061 | CS |
52 | 3.335 | 80.9466019417 | 4.12 | 13.68 | 2.18 | 393230 | 8.30195878 | CS |
156 | -4.685 | -38.5914332784 | 12.14 | 13.685 | 1.53 | 249801 | 6.32571048 | CS |
260 | -4.545 | -37.875 | 12 | 25.87 | 1.53 | 199284 | 7.20350074 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.